Interventional Oncology Market to Reach $2.9 billion by 2024 | Emerging Economies Offer High Growth Potential
According to
the new market research report "Interventional Oncology
Market by Product (Radiofrequency, microwave, cryoablation, embolization,
guidewires), Procedures (Thermal Ablation, Non-Thermal Ablation, TACE, TARE,
TAE), Cancer (Liver, Lung, Kidney, Bone Metastasis) - Global Forecast to 2024",
published by MarketsandMarkets™, the Interventional Oncology Market is
projected to reach USD 2.9
billion by
2024 from USD 2.0
billion in
2019, at a CAGR of 6.8%.
Don't miss out on business opportunities in Interventional
Oncology Market
Rising preference for minimally invasive procedures, increasing public-private
funding and government support for cancer research, technological advancements
in the field of interventional oncology, and increasing government investments
and funding for interventional oncology and related cancer research are some of
the major factors driving the growth of this market.
The TARE/SIRT segment accounted for the largest share of the Interventional
Oncology Market, by procedure, in 2018
Based on procedure, the Interventional Oncology Market is segmented into
thermal tumor ablation, non-thermal tumor ablation, transcatheter arterial
chemoembolization (TACE), transcatheter arterial radioembolization (TARE) or
selective internal radiation therapy (SIRT), and transcatheter arterial
embolization (TAE) or bland embolization. In 2018, the TARE/SIRT procedures
segment accounted for the largest market share majorly due to the rising
prevalence of cancer, increasing demand for minimally invasive procedures,
growing adoption of embolization procedures, and the clinical efficacy of
Yttrium-90 radioembolic agents (which are used in these procedures).
Browse and in-depth TOC on "Interventional Oncology
Market"
140 – Tables
33 – Figures
180 – Pages
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=203687164
Liver cancer segment to register the highest CAGR in the Interventional
Oncology Market, by application, during the forecast period
Based on cancer type, the Interventional Oncology Market is segmented into
liver cancer, kidney cancer, lung cancer, bone cancer, and other cancers
(includes pediatric cancer, prostate cancer, and breast cancer). Growth in this
segment can be attributed to factors such as rising cases of liver cancer
across the globe and growing initiatives/research activities for developing
advanced liver cancer therapies using interventional oncology.
North America accounted
for the largest share of the Interventional Oncology Market in 2018
The Interventional Oncology Market is segmented into four regional segments,
namely, North America, Europe, Asia Pacific, Latin America, and
the Middle East & Africa. North America accounted
for the largest share of the Interventional Oncology Market owing to factors
such as the rising incidence of cancer, easy accessibility to interventional
oncology, and the high adoption of technological advancements (owing to the
significant per capita annual healthcare expenditure by the US government).
Request Sample Report:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=203687164
The major players operating in the Interventional Oncology Market are Medtronic
(Ireland),
Boston Scientific (US), BTG plc (UK), Merit Medical Systems (US), and Terumo (Japan). The other
prominent players operating in the overall Interventional Oncology Market
include AngioDynamics (US), Ethicon (part of J&J) (US), Teleflex (US), Cook
Medical (US), HealthTronics (US), MedWaves Medical (US), Sanarus (US),
IMBiotechnologies (Canada),
Trod Medical (US), IceCure Medical (Israel), Mermaid Medicals (Denmark), and
Interface Biomaterials BV (Netherlands).
Medtronic (Ireland) dominated the global
interventional oncology market in 2017. The company focuses on adopting various
organic growth strategies like product launches & approvals and inorganic
growth strategies, such as acquisitions and collaborations, to expand its
presence and share in the interventional oncology market.
Comments
Post a Comment